| 查看: 2554 | 回复: 27 | |||
| 本帖产生 2 个 DRDEPI ,点击这里进行查看 | |||
| 当前只显示满足指定条件的回帖,点击这里查看本话题的所有回帖 | |||
狼行拂晓荣誉版主 (著名写手)
~~~~
|
[交流]
金秋之际话“丰收”,有奖分享经验总结活动,期待你的参与! 已有10人参与
|
||
|
金秋之际话“丰收”,有奖分享经验总结活动,期待你的参与!
【活动内容】
【活动目的】: [ Last edited by 狼行拂晓 on 2015-10-19 at 20:11 ] |
» 本帖已获得的红花(最新10朵)
» 猜你喜欢
请问怎么才能在有羧基存在的情况下,只给酚羟基上甲基
已经有6人回复
参比制剂,自己做的PK数据与IF资料报道的数据相差很大
已经有2人回复
药物学论文润色/翻译怎么收费?
已经有192人回复
祈求中本子
已经有0人回复
各位大佬,H口面上什么时候会评???
已经有30人回复
2026年山东大学海洋学院生物与医药博士招生-李霞课题组
已经有0人回复
博士研究生招生
已经有0人回复
药理学、临床药学方向 调剂
已经有1人回复
医药研发数据库资源
已经有4人回复
国自然意见求助
已经有74人回复

狼行拂晓
荣誉版主 (著名写手)
~~~~
- DRDEPI: 13
- 应助: 129 (高中生)
- 贵宾: 0.045
- 金币: 10341.8
- 散金: 619
- 红花: 57
- 帖子: 1289
- 在线: 877.3小时
- 虫号: 1037685
- 注册: 2010-06-07
- 性别: GG
- 专业: 药物化学
- 管辖: 新药研发
|
美国GDUFA中立卷审查(GDUFA INITIAL COMPLETENESS ASSESSMENT CHECKLIST FOR TYPE II API DMFs)的评审建议,同时要结合不接受标准ANDA Submissions –Refuse-to-Receive Standards Guidance for Industry: 3.2.S.2.1 Contains complete Manufacturer Information on the following for each site: Note: If a late stage intermediate has been outsourced, detailed information regarding the source for each supplier needs to be provided in section 2.3. Separate facilities used for release testing of the API and for additional processing (e.g. micronization) should also be listed. Central File Number or Facility Establishment Identifier numbers should be provided if available. 3.2.S.2.2 Contains Description of Manufacturing Process and Process Controls addressing the following: Note: DMF will not be considered complete for review requirements if the complete process is not included in the DMF or by appropriate reference to another DMF. If the firm chooses intermediates as “starting materials” a determination should be made if information is provided in the DMF to adequately evaluate their controls and effect on the drug substance quality and purity. 3.2.S.2.3 Contains information on the Control of Materials, as follows: Note: Specification, analytical protocol and representative CoA of each reagent/solvent should be provided. 3.2.S.2.4 Contains information for Controls of Critical Steps and Intermediates as follows: For sterile APIs. 3.2.S.4 Information is provided to support the Control of the Drug Substance as follows: Method validation reports may be included in section 3.2.R.3.S. |

10楼2015-10-12 22:49:57
凌宇雷池
超级版主 (文学泰斗)
小木虫科研大使\(^o^)/~
- DRDEPI: 1
- 应助: 758 (博后)
- 贵宾: 165.138
- 金币: 309516
- 散金: 91930
- 红花: 1123
- 沙发: 3529
- 帖子: 93408
- 在线: 56182小时
- 虫号: 659100
- 注册: 2008-11-21
- 性别: GG
- 专业: 生物化学
- 管辖: 科研生活区

2楼2015-10-09 22:23:35
News
专家顾问 (职业作家)
- DRDEPI: 6
- 应助: 366 (硕士)
- 贵宾: 0.025
- 金币: 5936.5
- 散金: 3206
- 红花: 155
- 沙发: 24
- 帖子: 4829
- 在线: 677.6小时
- 虫号: 1205015
- 注册: 2011-02-17
- 性别: GG
- 专业: 色谱分析
- 管辖: 生物医药区

3楼2015-10-11 09:07:20
狼行拂晓
荣誉版主 (著名写手)
~~~~
- DRDEPI: 13
- 应助: 129 (高中生)
- 贵宾: 0.045
- 金币: 10341.8
- 散金: 619
- 红花: 57
- 帖子: 1289
- 在线: 877.3小时
- 虫号: 1037685
- 注册: 2010-06-07
- 性别: GG
- 专业: 药物化学
- 管辖: 新药研发

5楼2015-10-11 12:45:41












回复此楼
News